Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Philip P Chamberlain

Showing results (1-10 of 25) with videos related to

Pageof 3
Sort By:
Cell Chemical Biology|March 23, 2019
Targeted Protein Degradation for Kinase SelectivityPhilip P Chamberlain
Nature Chemical Biology|June 13, 2018
Linkers for protein degradationPhilip P Chamberlain
Drug Discovery Today. Technologies|June 16, 2019
Cereblon modulators: Low molecular weight inducers of protein degradationPhilip P Chamberlain, Brian E Cathers
Nature Chemical Biology|September 19, 2019
Development of targeted protein degradation therapeuticsPhilip P Chamberlain, Lawrence G Hamann
Cell Cycle (Georgetown, Tex.)|February 1, 2008
Beyond IP3: roles for higher order inositol phosphates in immune cell signalingAndrew T Miller, Philip P Chamberlain, Michael P Cooke
Biochemistry|November 3, 2005
Structural insights into enzyme regulation for inositol 1,4,5-trisphosphate 3-kinase BPhilip P Chamberlain, Mark L Sandberg, Karsten Sauer, et al.
Methods in Molecular Biology (Clifton, N.J.)|August 25, 2021
Profiling CELMoD-Mediated Degradation of Cereblon NeosubstratesJoel W Thompson, Thomas Clayton, Gody Khambatta, et al.
Protein Expression and Purification|January 3, 2003
Cloning, expression, purification, and crystallisation of HIV-2 reverse transcriptaseLouise E Bird, Philip P Chamberlain, Guillaume B E Stewart-Jones, et al.
Journal of Medicinal Chemistry|April 20, 2007
Relationship of potency and resilience to drug resistant mutations for GW420867X revealed by crystal structures of inhibitor complexes for wild-type, Leu100Ile, Lys101Glu, and Tyr188Cys mutant HIV-1 reverse transcriptasesJingshan Ren, Charles E Nichols, Philip P Chamberlain, et al.
ACS Medicinal Chemistry Letters|December 21, 2019
Evolution of Cereblon-Mediated Protein Degradation as a Therapeutic ModalityPhilip P Chamberlain, Laura A D'Agostino, J Michael Ellis, et al.
Pageof 3

Showing results (1-10 of 25) with videos related to

Sort By:
Pageof 3
Cell Chemical Biology|March 23, 2019
Targeted Protein Degradation for Kinase SelectivityPhilip P Chamberlain
Nature Chemical Biology|June 13, 2018
Linkers for protein degradationPhilip P Chamberlain
Drug Discovery Today. Technologies|June 16, 2019
Cereblon modulators: Low molecular weight inducers of protein degradationPhilip P Chamberlain, Brian E Cathers
Nature Chemical Biology|September 19, 2019
Development of targeted protein degradation therapeuticsPhilip P Chamberlain, Lawrence G Hamann
Cell Cycle (Georgetown, Tex.)|February 1, 2008
Beyond IP3: roles for higher order inositol phosphates in immune cell signalingAndrew T Miller, Philip P Chamberlain, Michael P Cooke
Biochemistry|November 3, 2005
Structural insights into enzyme regulation for inositol 1,4,5-trisphosphate 3-kinase BPhilip P Chamberlain, Mark L Sandberg, Karsten Sauer, et al.
Methods in Molecular Biology (Clifton, N.J.)|August 25, 2021
Profiling CELMoD-Mediated Degradation of Cereblon NeosubstratesJoel W Thompson, Thomas Clayton, Gody Khambatta, et al.
Protein Expression and Purification|January 3, 2003
Cloning, expression, purification, and crystallisation of HIV-2 reverse transcriptaseLouise E Bird, Philip P Chamberlain, Guillaume B E Stewart-Jones, et al.
Journal of Medicinal Chemistry|April 20, 2007
Relationship of potency and resilience to drug resistant mutations for GW420867X revealed by crystal structures of inhibitor complexes for wild-type, Leu100Ile, Lys101Glu, and Tyr188Cys mutant HIV-1 reverse transcriptasesJingshan Ren, Charles E Nichols, Philip P Chamberlain, et al.
ACS Medicinal Chemistry Letters|December 21, 2019
Evolution of Cereblon-Mediated Protein Degradation as a Therapeutic ModalityPhilip P Chamberlain, Laura A D'Agostino, J Michael Ellis, et al.
Pageof 3